Access cutting-edge antineutrophilic cytoplasmic antibody (anca)- associated vasculitis (aav) treatment through this clinical trial at a research site in Minneapolis. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Minneapolis location
Preparing your pre-screening questions…
Access antineutrophilic cytoplasmic antibody (anca)- associated vasculitis (aav) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related antineutrophilic cytoplasmic antibody (anca)- associated vasculitis (aav) treatment provided free
Check if you qualify for this antineutrophilic cytoplasmic antibody (anca)- associated vasculitis (aav) clinical trial in Minneapolis, MN
No-Cost Study Care
Local to Minneapolis
Convenient for MN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
Sponsor: Fate Therapeutics
Yes, this clinical trial (NCT06308978) has an active research site in Minneapolis, MN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for antineutrophilic cytoplasmic antibody (anca)- associated vasculitis (aav) treatment options in Minneapolis, MN, this clinical trial (NCT06308978) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced antineutrophilic cytoplasmic antibody (anca)- associated vasculitis (aav) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all antineutrophilic cytoplasmic antibody (anca)- associated vasculitis (aav) clinical trials near you to find additional studies recruiting in your area.
See all heart attack clinical trials recruiting in Minneapolis — not just this study.
Browse Heart Attack Trials in Minneapolis →